NHS Framework Agreement for South of England Branded - Tranche B and Annual

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£339M
Sector
HEALTH
Published
12 Aug 2022
Delivery
01 Sep 2022 to 31 Aug 2024
Deadline
12 Apr 2022 13:00

Concepts

Location

Geochart for 1 buyers and 29 suppliers

1 buyer

29 suppliers

Description

NHS South of England Branded Medicines - Tranche B Offer reference number: CM/PHR/20/5611 CM/PHR/20/5611/01 - NHS Framework for SOUTH of England Branded Medicines - Tranche B. Period of framework: 1 September 2022 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5611/02 - NHS Framework for the SOUTH of England Branded Medicines - Annual Tranche. Period of framework: 1 September 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Award Detail

1 Mylan (Potters Bar)
  • Value: £338,655,597
2 Bayer (Reading)
  • Value: £338,655,597
3 Almirall (Uxbridge)
  • Value: £338,655,597
4 Biogen (Maidenhead)
  • Value: £338,655,597
5 Merck Sharpe & Dohme (London)
  • Value: £338,655,597
6 Ul Global Pharma (Watford)
  • Value: £338,655,597
7 Celltrion Healthcare (Slough)
  • Value: £338,655,597
8 Sobi Swedish Orphan Biovitrum (Great Abington)
  • Value: £338,655,597
9 CST Pharma (Walsall)
  • Value: £338,655,597
10 Ipsen (Slough)
  • Value: £338,655,597
11 Astrazeneca (London)
  • Value: £338,655,597
12 Thornton & Ross (Linthwaite)
  • Value: £338,655,597
13 Pfizer (None)
  • Value: £338,655,597
14 Glaxosmithkline (London)
  • Value: £338,655,597
15 Teva (Castleford)
  • Value: £338,655,597
16 Zentiva Pharma (London)
  • Value: £338,655,597
17 Accord (Barnstaple)
  • Value: £338,655,597
18 Merck Serono (Feltham)
  • Value: £338,655,597
19 Takeda (London)
  • Value: £338,655,597
20 Eli Lilly (Basingstoke)
  • Value: £338,655,597
21 Aventis Pharma (Reading)
  • Value: £338,655,597
22 Sandoz (None)
  • Value: £338,655,597
23 Roche Products (Welwyn Garden City)
  • Value: £338,655,597
24 Janssen Cilag (Highwycombe)
  • Value: £338,655,597
25 Ucb Pharma (Slough)
  • Value: £338,655,597
26 Novo Nordisk (Gatwick)
  • Value: £338,655,597
27 Organon Pharmaceuticals (London)
  • Value: £338,655,597
28 Gedeon Richter (London)
  • Value: £338,655,597
29 Typharm (Norwich)
  • Value: £338,655,597

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

Parties Appointed to the Framework - CMPHR205611 NHS Framework Agreement for South of England Branded - Tranche B and Annual Parties Appointed to the Framework - CMPHR205611 NHS Framework Agreement for South of England Branded - Tranche B and Annual.xlsx Document No. 10 - Participating Authorities (1) Document No. 10 - Participating Authorities (1).xls 220307 - FTS-004237 _ Salesforce - Enterprise Edition V2 220307 - FTS-004237 _ Salesforce - Enterprise Edition V2.pdf 220721 - Appendix 2 To Framework Agreement - TRANSPARENCY Award Schedule - CMPHR20561101 South of England Proprietary 220721 - Appendix 2 To Framework Agreement - TRANSPARENCY Award Schedule - CMPHR20561101 South of England Proprietary.pdf 220721 - Appendix 2 To Framework Agreement - TRANSPARENCY Award Schedule - CMPHR20561102 South of England Proprietary 220721 - Appendix 2 To Framework Agreement - TRANSPARENCY Award Schedule - CMPHR20561102 South of England Proprietary.pdf Document No. 03 - Framework Agreement and Terms and Conditions (2) Document No. 03 - Framework Agreement and Terms and Conditions (2).docx

Reference

Domains